MDxHealth SA (MDXH)
NASDAQ: MDXH · Real-Time Price · USD
2.290
-0.150 (-6.15%)
Mar 30, 2026, 4:00 PM EDT - Market closed
MDxHealth Revenue
In the year 2025, MDxHealth had annual revenue of $107.88M with 19.80% growth. MDxHealth had revenue of $29.55M in the quarter ending December 31, 2025, with 19.43% growth.
Revenue (ttm)
$107.88M
Revenue Growth
+19.80%
P/S Ratio
1.09
Revenue / Employee
$345,753
Employees
312
Market Cap
117.62M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 107.88M | 17.83M | 19.80% |
| Dec 31, 2024 | 90.05M | 19.86M | 28.29% |
| Dec 31, 2023 | 70.19M | 33.14M | 89.43% |
| Dec 31, 2022 | 37.05M | 14.82M | 66.62% |
| Dec 31, 2021 | 22.24M | 3.78M | 20.47% |
| Dec 31, 2020 | 18.46M | 6.68M | 56.64% |
| Dec 31, 2019 | 11.79M | -16.61M | -58.50% |
| Dec 31, 2018 | 28.40M | -12.11M | -29.90% |
| Dec 31, 2017 | 40.51M | 10.54M | 35.16% |
| Dec 31, 2016 | 29.97M | 12.33M | 69.90% |
| Dec 31, 2015 | 17.64M | 5.97M | 51.14% |
| Dec 31, 2014 | 11.67M | 4.12M | 54.50% |
| Dec 31, 2013 | 7.55M | 1.64M | 27.75% |
| Dec 31, 2012 | 5.91M | 2.17M | 58.10% |
| Dec 31, 2011 | 3.74M | 349.41K | 10.31% |
| Dec 31, 2010 | 3.39M | -262.90K | -7.20% |
| Dec 31, 2009 | 3.65M | -560.84K | -13.31% |
| Dec 31, 2008 | 4.21M | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | 3.64M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Myriad Genetics | 824.50M |
| Castle Biosciences | 344.23M |
| Fulgent Genetics | 322.67M |
| FONAR | 106.03M |
| Prenetics Global | 92.39M |
| Biodesix | 88.50M |
| Burning Rock Biotech | 77.14M |
| Personalis | 69.65M |
MDXH News
- 14 days ago - Mdxhealth Highlights Data from Oxford's ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026 - GlobeNewsWire
- 4 weeks ago - MDxHealth SA (MDXH) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26 - GlobeNewsWire
- 2 months ago - MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences - GlobeNewsWire
- 2 months ago - Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer - GlobeNewsWire
- 4 months ago - MDxHealth SA (MDXH) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 months ago - Angle PLC Announces Strategy Update - Accesswire
- 8 months ago - Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne - GlobeNewsWire